Journal
MATURITAS
Volume 51, Issue 2, Pages 113-126Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.maturitas.2005.01.012
Keywords
osteoporosis; hormone replacement therapy; postmenopausal
Categories
Ask authors/readers for more resources
Osteoporosis is a common condition in postmenopausal women and is associated with significant healthcare costs, morbidity and mortality. It is clear that long-term hormone replacement therapy (HRT) has a role to play in preventing osteoporosis by increasing bone mineral density and reducing fracture rate. It is important that these benefits, as well as those on climacteric symptoms, quality of life. colorectal carcinoma and cognition, are not underestimated in the face of the Postulated risks with regard to breast cancer and cardiovascular disease. In conclusion, HRT should currently be used only for women with climacteric symptoms or an increased risk of osteoporosis, and it is important that there is an individualised approach to treatment based on each woman's risk profile. (c) 2005 Published by Elsevier Ireland Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available